Elatatug

艾拉妥塔单抗

Report date: 2026/04/16 20:00:17

Base Information

Drug NameElatatug
Drug Alias NameTORL-2-307-MAB
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunomodulatorsClaudin-18 splice variant 2 antagonists
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursPancreatic Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTorl Biotherapeutics LLC
China Registration ClassN/A

Develop Information

Active CompaniesTorl Biotherapeutics LLC
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursPancreatic Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A